249 related articles for article (PubMed ID: 19114973)
21. [Ifosfamide treatment for children with malignant tumor].
Muchi H; Taniguchi Y; Makino S
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3291-4. PubMed ID: 3688893
[TBL] [Abstract][Full Text] [Related]
22. Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue.
Snyder M; Gangadhara S; Brohl AS; Ludlow S; Nanjappa S
Cancer Control; 2017; 24(5):1073274817729070. PubMed ID: 28975823
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity.
Richards A; Marshall H; McQuary A
J Oncol Pharm Pract; 2011 Dec; 17(4):372-80. PubMed ID: 20861178
[TBL] [Abstract][Full Text] [Related]
24. Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.
Brunello A; Basso U; Rossi E; Stefani M; Ghiotto C; Marino D; Crivellari G; Monfardini S
Drugs Aging; 2007; 24(11):967-73. PubMed ID: 17953463
[TBL] [Abstract][Full Text] [Related]
25. Ifosfamide neurotoxicity. A challenge for nurses, a potential nightmare for patients.
Cameron JC
Cancer Nurs; 1993 Feb; 16(1):40-6. PubMed ID: 8384523
[TBL] [Abstract][Full Text] [Related]
26. Neurological toxicity of ifosfamide.
Nicolao P; Giometto B
Oncology; 2003; 65 Suppl 2():11-6. PubMed ID: 14586141
[TBL] [Abstract][Full Text] [Related]
27. Important role of thiamine in preventing ifosfamide-induced encephalopathy.
Lombardi G; Zustovich F; Nicoletto MO; Donach M; Pastorelli D
J Oncol Pharm Pract; 2010 Jun; 16(2):135-6. PubMed ID: 19692431
[No Abstract] [Full Text] [Related]
28. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
Goren MP; Epelman S; Bush DA
Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
[TBL] [Abstract][Full Text] [Related]
29. Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity.
Giovanis P; Garna A; Marcante M; Nardi K; Giusto M
Tumori; 2009; 95(4):545-6. PubMed ID: 19856674
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of ifosfamide and some metabolites in children.
Kaijser GP; De Kraker J; Bult A; Underberg WJ; Beijnen JH
Anticancer Res; 1998; 18(3B):1941-9. PubMed ID: 9677448
[TBL] [Abstract][Full Text] [Related]
31. Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report.
Cherry MA; Bhardwaj H; Hopps S; Srour S; Pant S
J Oncol Pharm Pract; 2013 Sep; 19(3):261-4. PubMed ID: 23135805
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue.
Aeschlimann C; Cerny T; Küpfer A
Drug Metab Dispos; 1996 Dec; 24(12):1336-9. PubMed ID: 8971139
[TBL] [Abstract][Full Text] [Related]
33. Severe ifosfamide-induced neurotoxicity: a case report.
Ramos Linares S; Breña Atienza J; Cháfer Rudilla M; Ríos Rull P; Cabello Rodríguez A; Merino Alonso J
Pharm World Sci; 2010 Apr; 32(2):109-11. PubMed ID: 20033290
[TBL] [Abstract][Full Text] [Related]
34. Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
Brain EG; Rezai K; Weill S; Gauzan MF; Santoni J; Besse B; Goupil A; Turpin F; Urien S; Lokiec F
Cancer Chemother Pharmacol; 2007 Aug; 60(3):375-81. PubMed ID: 17106751
[TBL] [Abstract][Full Text] [Related]
35. Ifosfamide encephalopathy.
Ajithkumar T; Parkinson C; Shamshad F; Murray P
Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):108-14. PubMed ID: 17355105
[TBL] [Abstract][Full Text] [Related]
36. Cerebral formation in situ of S-carboxymethylcysteine after ifosfamide administration to mice: a further clue to the mechanism of ifosfamide encephalopathy.
Lerch S; Küpfer A; Idle JR; Lauterburg BH
Toxicol Lett; 2006 Mar; 161(3):188-94. PubMed ID: 16229978
[TBL] [Abstract][Full Text] [Related]
37. Ifosfamide induced encephalopathy in a child with osteosarcoma.
Sarbay H; Demir ÜF; Yılmaz G; Atay AA; Malbora B
J Oncol Pharm Pract; 2021 Jul; 27(5):1302-1306. PubMed ID: 33023384
[TBL] [Abstract][Full Text] [Related]
38. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
Szabatura AH; Cirrone F; Harris C; McDonnell AM; Feng Y; Voit D; Neuberg D; Butrynski J; Fisher DC
J Oncol Pharm Pract; 2015 Jun; 21(3):188-93. PubMed ID: 24664476
[TBL] [Abstract][Full Text] [Related]
39. Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer.
Ataseven E; Göktepe ŞÖ; Kantar M
J Oncol Pharm Pract; 2021 Dec; 27(8):2018-2022. PubMed ID: 33779369
[TBL] [Abstract][Full Text] [Related]
40. New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity.
Storme T; Deroussent A; Mercier L; Prost E; Re M; Munier F; Martens T; Bourget P; Vassal G; Royer J; Paci A
J Pharmacol Exp Ther; 2009 Feb; 328(2):598-609. PubMed ID: 19017849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
